# IL-21-modulated CD8+ antigen-specific T cells with cyclophosphamide and aldesleukin in metastatic melanoma (Fred Hutchinson phase 1, terminated)

Source: https://onco.cc/trials/nct01106235/  
OnCo record `nct01106235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Seattle trial of melanoma-targeting T cells treated in the laboratory with the immune signal IL-21 before infusion. The registry lists it as terminated in 2011 and gives no reason.

## Summary

The registry describes a phase I study of autologous interleukin-21-modulated CD8+ antigen-specific T cells, with cyclophosphamide and aldesleukin, in metastatic melanoma, started in April 2010, with an estimated enrolment of 12 (ClinicalTrials.gov NCT01106235). Its overall status is terminated, with primary completion in November 2011 and no reason for stopping recorded; Cassian Yee is listed as principal investigator (ClinicalTrials.gov NCT01106235). No results are posted.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-05
- Registry id: NCT01106235
- Phase: 1
- Setting: Stage IV melanoma: autologous CD8+ antigen-specific T cells modulated with interleukin-21 in the laboratory, with cyclophosphamide and aldesleukin
- Sponsor: Fred Hutchinson Cancer Center, with the National Cancer Institute
- Result: Terminated, with no reason given on the registry; no results posted.

## Sources

- ClinicalTrials.gov NCT01106235: https://clinicaltrials.gov/study/NCT01106235

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Aldesleukin (high-dose IL-2)](https://onco.cc/drugs/aldesleukin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/)
- institutions: [Fred Hutchinson Cancer Center](https://onco.cc/institutions/fred-hutch/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [Endogenous T-cell therapy](https://onco.cc/terms/endogenous-t-cell-therapy/)
- people: [Cassian Yee](https://onco.cc/people/cassian-yee/)

---
JSON: https://onco.cc/api/v1/entities/nct01106235.json